Previous Close | 3.0900 |
Open | 3.1200 |
Bid | 3.1000 x 1100 |
Ask | 3.1100 x 2200 |
Day's Range | 3.0650 - 3.2000 |
52 Week Range | 2.4200 - 11.0000 |
Volume | |
Avg. Volume | 1,206,204 |
Market Cap | 1.333B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1820 |
Earnings Date | May 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for VCSA
PORTLAND, Ore., June 28, 2022--Vacasa (Nasdaq: VCSA), North America's leading vacation rental management platform, released the second edition of its Vacation Rental Search Report today, utilizing 12 months of Vacasa.com data to break down the top guest preferences and booking patterns. Findings in the 2022 Vacation Rental Search Report detail the overarching travel trends shaping how guests search for and secure their stays, as well as which amenities and destinations are proving to be most pop
Vacasa, Inc. ( NASDAQ:VCSA ) shareholders (or potential shareholders) will be happy to see that the Independent...
Absci Corp. (Nasdaq: ABSI), a Vancouver, Washington-based synthetic biology company that went public last July, is down 59% so far this year, as the biotech sector as a whole takes a beating. Absci’s stock was trading at $3.42 on Thursday, down from a high of $31.53 on Aug. 4, 2021. The Nasdaq Biotechnology Index is down 27.5% year to date, less than Absci's decline, but still the "worst drawdown" many analysts have seen in 20 years, according to MarketWatch.